Topline data
-
.Dyne Therapeutics to Hold Investor Call and Webcast on Top‑Line Results of the DELIVER Trial’s Registrational Expansion Cohort for Z‑Rostudirsen (DYNE‑251) in Duchenne Muscular Dystrophy – Dec 8, 8 a.m. ET
words.Dyne Therapeutics (Nasdaq: DYN) will release top‑line results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial for zeleciment rostudirsen (DYNE‑251) on December 8 2025 at 8:00 a.m. ET via an investor webcast, with a press release beforehand and a 90‑day replay. The stock closed at $20.28, trading above its 200‑day moving average and showing modestly elevated volume. Historical patterns suggest clinical milestones can trigger sharp short‑term price swings.
